Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG.
Siddiqi T, et al. Among authors: kipps tj.
Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895.
Blood. 2022.
PMID: 34699592
Free PMC article.
Clinical Trial.